Canada Spends Logo

Explore our Budget 2026 analysis

Grant: Project Grant - Priority Announcement: Infection and Immunity

Université Laval

$100,000.00

Dual function of autoantibodies in a model of multiple sclerosis

FY 2022-23

Summary
Autoimmune demyelinating diseases, such as multiple sclerosis (MS), result from dysfunctions of the immune system that cause it to destroy myelin in the nervous system. As B cells (a type of immune cells) play key roles in these diseases, B cell-depleting drugs have proven remarkably effective and are now part of the first-line therapeutic arsenal. A PROBLEM is that these drugs deplete most B cells, including beneficial ones, increasing the risk of infection. Moreover, they are not curative, possibly sparing a subset of B cells that secrete disease-promoting antibodies. Indeed, some self-reactive antibodies (autoantibodies) have been shown to be pathogenic in MS-related diseases and animal models. However, most autoantibodies have no known role. The GENERAL GOAL of this project is to clarify the nature of myelin-specific antibodies, in the hope of finding novel therapeutic approaches. We have recently characterized such autoantibodies in a new mouse model of MS. Our HYPOTHESIS is that most are nonpathogenic and can even be protective. To test this, our SPECIFIC AIMS will be to examine how our MS model is affected by: 1) interventions aimed at eliminating anti-myelin antibodies; and 2) treatments with anti-myelin antibodies with or without a mutation that blocks all effector functions. To this end, we will take benefit of cutting-edge technologies and ongoing collaborations with antibody manufacturers. This project will provide not only BASIC KNOWLEDGE on the dichotomous role of autoantibodies, which may help to understand how autoimmunity can develop, but also TRANSLATIONAL KNOWLEDGE on two potential treatments (plasmablast depletion and administration of protective autoantibodies).
Program
Project Grant - Priority Announcement: Infection and Immunity
Location
Quebec, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database

As published

Id
472921
Name
Vallières Luc
Region
Québec
Country
Canada
Orgtype
Institution Paid; Research Institution
Instname2
Infection and Immunity
Theme2
Biomedical
Prcname2
Systems & Circuits Neurosciences - A
Projecttitle
Dual function of autoantibodies in a model of multiple sclerosis
Programtype2
Operating Grants
Orgnameinp2
Université Laval
Cihramount2
$100,000
Cihrequipment2
$0
Programname2
Project Grant - Priority Announcement: Infection and Immunity
Keyworddelim
Anti-Mog Antibodies; Autoantibodies; Demyelinating Autoimmune Diseases; Experimental Autoimmune Encephalomyelitis (Eae); Mog Antibody Disease (Mogad); Multiple Sclerosis; Neuroimmunology; Neuroinflammation; Plasmablasts
Abstract
Autoimmune demyelinating diseases, such as multiple sclerosis (MS), result from dysfunctions of the immune system that cause it to destroy myelin in the nervous system. As B cells (a type of immune cells) play key roles in these diseases, B cell-depleting drugs have proven remarkably effective and are now part of the first-line therapeutic arsenal. A PROBLEM is that these drugs deplete most B cells, including beneficial ones, increasing the risk of infection. Moreover, they are not curative, possibly sparing a subset of B cells that secrete disease-promoting antibodies. Indeed, some self-reactive antibodies (autoantibodies) have been shown to be pathogenic in MS-related diseases and animal models. However, most autoantibodies have no known role. The GENERAL GOAL of this project is to clarify the nature of myelin-specific antibodies, in the hope of finding novel therapeutic approaches. We have recently characterized such autoantibodies in a new mouse model of MS. Our HYPOTHESIS is that most are nonpathogenic and can even be protective. To test this, our SPECIFIC AIMS will be to examine how our MS model is affected by: 1) interventions aimed at eliminating anti-myelin antibodies; and 2) treatments with anti-myelin antibodies with or without a mutation that blocks all effector functions. To this end, we will take benefit of cutting-edge technologies and ongoing collaborations with antibody manufacturers. This project will provide not only BASIC KNOWLEDGE on the dichotomous role of autoantibodies, which may help to understand how autoimmunity can develop, but also TRANSLATIONAL KNOWLEDGE on two potential treatments (plasmablast depletion and administration of protective autoantibodies).
Competitiondate
202209
Approvedterm2
1 yr 0 mth
Pinamesdelim
Vallières, Luc
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $100,000~ $0~